Clearance of Strongyloides stercoralis infection using ivermectin improves kidney function and modulates untargeted urinary metabolomics (2026)

Peer-Reviewed Study · Tunbenjasiri K, Kongsintaweesuk S, Chaiyachate K, Mon AM, et al. · 2026

Tunbenjasiri K et al., 2026: Exploratory before-and-after study of 15 patients with early chronic kidney disease and strongyloidiasis treated with ivermectin, finding some kidney-function and metabolite changes but no significant global metabolomic shift.

Global multivariate analyses did not demonstrate statistically significant separation between pre- and post-treatment urinary metabolomic profiles.

Tunbenjasiri K et al., 2026: Exploratory before-and-after study of 15 patients with early chronic kidney disease and strongyloidiasis treated with ivermectin, finding some kidney-function and metabolite changes but no significant global metabolomic shift. Exploratory before-and-after longitudinal study, N=15 patients with CKD stages 1-3 and confirmed strongyloidiasis, Thailand; ivermectin anthelmintic treatment with follow-up at 17 months; LC/Q-TOF urinary metabolomics. No control group (before-after design). Authors declare no competing interests. Bearing PARTLY SUPPORTS: the metabolic effect observed is mediated by clearing the parasite, not by an intrinsic metabolic action of the drug , which is the honest reading of the 'metabolic claims' item in C7. Study type: uncontrolled series.